Potential impact of expanded insurance coverage for ondansetron on prophylactic antiemetic prescriptions given and postoperative antiemetics delivered among patients undergoing general anaesthesia in Japan: a retrospective observational study using i

Background The impact of expanding health insurance coverage for ondansetron on antiemetic prescription trends and postoperative nausea and vomiting (PONV) in Japan remains unknown. This nationwide Japanese descriptive study evaluated the impact of the coverage expansion on clinical practice and patient outcomes. Methods This large-scale retrospective observational study using an interruped time-series analysis (ITSA) analysed a nationwide health insurance claims database from more than 500 institutions in Japan (February 2020 to March 2024). The primary outcome was prophylactic and rescue antiemetic prescriptions given, and the secondary outcome was PONV the estimated occurence of PONV based on antiemetic treatment. Prescriptions on surgery day and postoperative days 1–2 were used as surrogate measures of prophylactic antiemetic use and pharmacologically treated (rescue-medicated) PONV, respectively; these surrogates were not direct measures of clinically observed PONV. Results A total of 2 150 497 general anaesthesia cases (2 022 695 adults; 127 802 children) were analysed. After coverage expansion, prophylactic antiemetic prescriptions increased (total prescriptions, from 492 998 of 1 052 933 [46.8%] to 636 158 of 1 097 564 [58.0%]; ≥2 prescriptions, from 92 134 of 1 052 933 [8.8%] to 246 572 of 1 097 564 [22.5%]). ITSA showed that ondansetron prescriptions increased significantly after coverage expansion (β=0.33; 95% confidence interval [CI] 0.23–0.43; P <0.001). The combined effect of guideline release and coverage expansion was associated with a significant downward trend in pharmacologically treated PONV (β=−0.050; 95% CI −0.093 to −0.0079; P =0.021). Conclusions Established clinical guidelines and expanded insurance coverage of ondansetron were associated with changes in perioperative antiemetic prescribing and a modest decline in pharmacologically treated PONV in Japan. As a retrospective observational study, causality cannot be confirmed, and further studies are needed to assess generalisability.

Authors

Institutions

Publication Details

Journal
BJA Open
Published
2026-11-18
DOI
https://doi.org/10.1016/j.bjao.2026.100897
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Potential impact of expanded insurance coverage for ondansetron on prophylactic antiemetic prescriptions given and postoperative antiemetics delivered among patients undergoing general anaesthesia in Japan: a retrospective observational study using i

Taiki Kojima, 公昭 中村
BJA Open
Nausea and vomiting management
article

Potential impact of expanded insurance coverage for ondansetron on prophylactic antiemetic prescriptions given and postoperative antiemetics delivered among patients undergoing general anaesthesia in Japan: a retrospective observational study using i

Taiki Kojima, 公昭 中村
article en

Abstract

Background The impact of expanding health insurance coverage for ondansetron on antiemetic prescription trends and postoperative nausea and vomiting (PONV) in Japan remains unknown. This nationwide Japanese descriptive study evaluated the impact of the coverage expansion on clinical practice and patient outcomes. Methods This large-scale retrospective observational study using an interruped time-series analysis (ITSA) analysed a nationwide health insurance claims database from more than 500 institutions in Japan (February 2020 to March 2024). The primary outcome was prophylactic and rescue antiemetic prescriptions given, and the secondary outcome was PONV the estimated occurence of PONV based on antiemetic treatment. Prescriptions on surgery day and postoperative days 1–2 were used as surrogate measures of prophylactic antiemetic use and pharmacologically treated (rescue-medicated) PONV, respectively; these surrogates were not direct measures of clinically observed PONV. Results A total of 2 150 497 general anaesthesia cases (2 022 695 adults; 127 802 children) were analysed. After coverage expansion, prophylactic antiemetic prescriptions increased (total prescriptions, from 492 998 of 1 052 933 [46.8%] to 636 158 of 1 097 564 [58.0%]; ≥2 prescriptions, from 92 134 of 1 052 933 [8.8%] to 246 572 of 1 097 564 [22.5%]). ITSA showed that ondansetron prescriptions increased significantly after coverage expansion (β=0.33; 95% confidence interval [CI] 0.23–0.43; P <0.001). The combined effect of guideline release and coverage expansion was associated with a significant downward trend in pharmacologically treated PONV (β=−0.050; 95% CI −0.093 to −0.0079; P =0.021). Conclusions Established clinical guidelines and expanded insurance coverage of ondansetron were associated with changes in perioperative antiemetic prescribing and a modest decline in pharmacologically treated PONV in Japan. As a retrospective observational study, causality cannot be confirmed, and further studies are needed to assess generalisability.

BJA OpenVol. 20
Maruishi Pharmaceutical (Japan) (JP), Aichi Children's Health and Medical Center (JP)
Good health and well-being
Nausea and vomiting management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon